Many investors use Sharesight’s portfolio tracker to track the assets in their SMSF, as it allows them to track the performance of investments in global markets and a range of asset classes. As can be seen in the chart above, the month of August saw wide-ranging investments by SMSFs, with Mesoblast (ASX: MSB) and Commonwealth Bank (ASX: CBA) leading in both buy and sell trades, while investors also favoured Resmed (ASX: RMD), Afterpay (ASX: APT) and CSL (ASX: CSL). Here’s the news behind some of August’s most interesting stocks:
- Mesoblast (ASX: MSB) is a growing Australian biotech company that has seen surging share prices and a 90% increase in its revenue over the past year. The next few months will be critical for Mesoblast; the company is seeking FDA approval for its stem cell treatment, and is planning to launch a drug to treat Covid-19 complications by the end of 2020.
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-6277
-
- There are more pages in this discussion • 11,518 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
4 | 71034 | 0.980 |
2 | 3059 | 0.975 |
7 | 145890 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 1132 | 1 |
1.000 | 9500 | 3 |
1.005 | 35000 | 1 |
1.010 | 58113 | 4 |
1.015 | 46100 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online